{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:23:49Z","timestamp":1787009029019,"version":"build-2736575974"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T00:00:00Z","timestamp":1596067200000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002141","name":"Public Health England","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002141","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute for Health Research Health Protection Research Unit"},{"name":"Blood Borne and Sexually Transmitted Infections"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>HIV treatment guidelines have traditionally recommended that all HIV-positive individuals are tested for evidence of drug resistance prior to starting ART. Testing for resistance to reverse transcriptase inhibitors and PIs is well established in routine care. However, testing for integrase strand transfer inhibitor (InSTI) resistance is less consistent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To inform treatment guidelines by determining the prevalence of InSTI resistance in a national cohort of recently infected individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>Recent (within 4\u2009months) HIV-1 infections were identified using a Recent Infection Testing Algorithm of new HIV-1 diagnoses in the UK. Resistance-associated mutations (RAMs) in integrase, protease and reverse transcriptase were detected by ultradeep sequencing, which allows for the sensitive estimation of the frequency of each resistant variant in a sample.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The analysis included 655 randomly selected individuals (median age\u2009=\u200933\u2009years, 95% male, 83% MSM, 78% white) sampled in the period 2014 to 2016 and determined to have a recent infection. These comprised 320, 138 and 197 samples from 2014, 2015 and 2016, respectively. None of the samples had major InSTI RAMs occurring at high variant frequency (\u226520%). A subset (25\/640, 3.9%) had major InSTI RAMs occurring only as low-frequency variants (2%\u201320%). In contrast, 47\/588 (8.0%) had major reverse transcriptase inhibitor and PI RAMs at high frequency.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Between 2014 and 2016, major InSTI RAMs were uncommon in adults with recent HIV-1 infection, only occurring as low-frequency variants of doubtful clinical significance. Continued surveillance of newly diagnosed patients for evidence of transmitted InSTI resistance is recommended to inform clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaa309","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T15:15:33Z","timestamp":1592925333000},"page":"3311-3318","source":"Crossref","is-referenced-by-count":27,"title":["Surveillance of HIV-1 transmitted integrase strand transfer inhibitor resistance in the UK"],"prefix":"10.1093","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0348-9679","authenticated-orcid":false,"given":"Jean L","family":"Mbisa","sequence":"first","affiliation":[{"name":"National Infection Service, Public Health England, London, UK"},{"name":"National Institute for Health Research (NIHR) Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ledesma","sequence":"additional","affiliation":[{"name":"National Infection Service, Public Health England, London, UK"},{"name":"National Institute for Health Research (NIHR) Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kirwan","sequence":"additional","affiliation":[{"name":"National Infection Service, Public Health England, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F","family":"Bibby","sequence":"additional","affiliation":[{"name":"National Infection Service, Public Health England, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Manso","sequence":"additional","affiliation":[{"name":"National Infection Service, Public Health England, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Skingsley","sequence":"additional","affiliation":[{"name":"National Infection Service, Public Health England, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Murphy","sequence":"additional","affiliation":[{"name":"National Infection Service, Public Health England, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Brown","sequence":"additional","affiliation":[{"name":"National Infection Service, Public Health England, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T","family":"Dunn","sequence":"additional","affiliation":[{"name":"Institute for Global Health, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Delpech","sequence":"additional","affiliation":[{"name":"National Infection Service, Public Health England, London, UK"},{"name":"National Institute for Health Research (NIHR) Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Geretti","sequence":"additional","affiliation":[{"name":"Institute of Infection and Global Health, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,7,29]]},"reference":[{"key":"2020101604545994300_dkaa309-B1","first-page":"341","article-title":"Advances in antiretroviral therapy","volume":"8","author":"Arribas","year":"2013","journal-title":"Curr Opin HIV AIDS"},{"key":"2020101604545994300_dkaa309-B2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40121-013-0020-8","article-title":"Integrase strand transfer inhibitors in HIV therapy","volume":"2","author":"Mesplede","year":"2013","journal-title":"Infect Dis Ther"},{"key":"2020101604545994300_dkaa309-B3","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/QAI.0000000000000790","article-title":"Brief report: dolutegravir plus abacavir\/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial","volume":"70","author":"Walmsley","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020101604545994300_dkaa309-B4","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"2020101604545994300_dkaa309-B5","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"2020101604545994300_dkaa309-B6","doi-asserted-by":"crossref","first-page":"e02533","DOI":"10.1128\/AAC.02533-18","article-title":"Resistance analysis of bictegravir-emtricitabine-tenofovir alafenamide in HIV-1 treatment-naive patients through 48 weeks","volume":"63","author":"Acosta","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020101604545994300_dkaa309-B7","doi-asserted-by":"crossref","first-page":"s2","DOI":"10.1111\/hiv.12426","article-title":"British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy","volume":"17","author":"Churchill","year":"2015","journal-title":"HIV Med"},{"key":"2020101604545994300_dkaa309-B8"},{"key":"2020101604545994300_dkaa309-B9","year":"2018"},{"key":"2020101604545994300_dkaa309-B10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/cid\/ciy463","article-title":"Human immunodeficiency virus drug resistance: 2018 recommendations of the International Antiviral Society\u2013USA Panel","volume":"68","author":"Gunthard","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020101604545994300_dkaa309-B11","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1086\/496984","article-title":"Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis","volume":"41","author":"Sax","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2020101604545994300_dkaa309-B12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1086\/375597","article-title":"Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel","volume":"37","author":"Hirsch","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2020101604545994300_dkaa309-B13","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1097\/QAD.0b013e3280b07761","article-title":"UK Collaborative HIV Cohort Study, UK Register of HIV Seroconverters. Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom","volume":"21","year":"2007","journal-title":"AIDS"},{"key":"2020101604545994300_dkaa309-B14","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/hiv.12414","article-title":"Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom","volume":"18","author":"Tostevin","year":"2017","journal-title":"HIV Med"},{"key":"2020101604545994300_dkaa309-B15","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/QCO.0b013e32835a1de7","article-title":"Emerging patterns and implications of HIV-1 integrase inhibitor resistance","volume":"25","author":"Geretti","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"2020101604545994300_dkaa309-B16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2217\/fvl.10.77","article-title":"New technology to detect low-level drug-resistant HIV variants","volume":"6","author":"Gega","year":"2011","journal-title":"Future Virol"},{"key":"2020101604545994300_dkaa309-B17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/QCO.0000000000000136","article-title":"Transmission of HIV drug resistance: lessons from sensitive screening assays","volume":"28","author":"Geretti","year":"2015","journal-title":"Curr Opin Infect Dis"},{"key":"2020101604545994300_dkaa309-B18","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jama.2011.375","article-title":"Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis","volume":"305","author":"Li","year":"2011","journal-title":"JAMA"},{"key":"2020101604545994300_dkaa309-B19","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/jac\/dku426","article-title":"Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing","volume":"70","author":"Cozzi-Lepri","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2020101604545994300_dkaa309-B20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/jac\/dkx366","article-title":"No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir","volume":"73","author":"Perrier","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2020101604545994300_dkaa309-B21","first-page":"1136","article-title":"Determining the origins of HIV-1 drug-resistant minority variants in people who are recently infected using phylogenetic reconstruction","volume":"69","author":"Mbisa","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2020101604545994300_dkaa309-B22","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1093\/jac\/dkv202","article-title":"Primary resistance to integrase strand-transfer inhibitors in Europe","volume":"70","author":"Casadella","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2020101604545994300_dkaa309-B23","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1093\/jac\/dkv243","article-title":"Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades","volume":"70","author":"Doyle","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2020101604545994300_dkaa309-B24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3851\/IMP2780","article-title":"Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013","volume":"20","author":"Stekler","year":"2015","journal-title":"Antivir Ther"},{"key":"2020101604545994300_dkaa309-B25","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/jac\/dkz067","article-title":"Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice","volume":"74","author":"Alvarez","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2020101604545994300_dkaa309-B26","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/aid.2018.0272","article-title":"Absence of integrase strand transfer inhibitor associated resistance in antiretroviral therapy na\u00efve and experienced individuals from Western India","volume":"35","author":"Karade","year":"2019","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2020101604545994300_dkaa309-B27","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/QAI.0000000000001649","article-title":"Prevalence of primary drug resistance against HIV-1 integrase inhibitors in Canada","volume":"78","author":"Ji","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020101604545994300_dkaa309-B28","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1093\/jac\/dkv048","article-title":"Highly frequent HIV-1 minority resistant variants at baseline of the ANRS 139 TRIO trial had a limited impact on virological response","volume":"70","author":"Charpentier","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2020101604545994300_dkaa309-B29","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/15284336.2016.1142731","article-title":"Rare emergence of drug resistance in HIV-1 treatment-na\u00efve patients after 48 weeks of treatment with elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide","volume":"17","author":"Margot","year":"2016","journal-title":"HIV Clin Trials"},{"key":"2020101604545994300_dkaa309-B30","doi-asserted-by":"crossref","first-page":"35779","DOI":"10.1038\/srep35779","article-title":"Prevalence of integrase strand transfer inhibitors (INSTI) resistance mutations in Taiwan","volume":"6","author":"Chang","year":"2016","journal-title":"Sci Rep"},{"key":"2020101604545994300_dkaa309-B31","doi-asserted-by":"crossref","first-page":"20673","DOI":"10.2807\/1560-7917.ES2014.19.2.20673","article-title":"Recent infection testing algorithm (RITA) applied to new HIV diagnoses in England, Wales and Northern Ireland, 2009 to 2011","volume":"19","author":"Aghaizu","year":"2014","journal-title":"Euro Surveill"},{"key":"2020101604545994300_dkaa309-B32","doi-asserted-by":"crossref","first-page":"e33328","DOI":"10.1371\/journal.pone.0033328","article-title":"Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies","volume":"7","author":"Duong","year":"2012","journal-title":"PLoS One"},{"key":"2020101604545994300_dkaa309-B33","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1097\/QAD.0000000000001209","article-title":"Viral load criteria and threshold optimization to improve HIV incidence assay characteristics","volume":"30","author":"Kassanjee","year":"2016","journal-title":"AIDS"},{"key":"2020101604545994300_dkaa309-B34","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/jac\/dkw404","article-title":"Enhanced surveillance of HIV-1 drug resistance in recently infected MSM in the UK","volume":"72","author":"Cunningham","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2020101604545994300_dkaa309-B35","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"key":"2020101604545994300_dkaa309-B36","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1089\/cmb.2012.0021","article-title":"SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing","volume":"19","author":"Bankevich","year":"2012","journal-title":"J Comput Biol"},{"key":"2020101604545994300_dkaa309-B37","doi-asserted-by":"crossref","first-page":"e0143081","DOI":"10.1371\/journal.pone.0143081","article-title":"Assessment of the utility of whole genome sequencing of measles virus in the characterisation of outbreaks","volume":"10","author":"Penedos","year":"2015","journal-title":"PLoS One"},{"key":"2020101604545994300_dkaa309-B38","doi-asserted-by":"crossref","first-page":"e4724","DOI":"10.1371\/journal.pone.0004724","article-title":"Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update","volume":"4","author":"Bennett","year":"2009","journal-title":"PLoS One"},{"key":"2020101604545994300_dkaa309-B39","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jac\/dkz417","article-title":"Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance","volume":"75","author":"Tzou","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2020101604545994300_dkaa309-B40","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/bioinformatics\/btp134","article-title":"The calibrated population resistance tool: standardized genotypic estimation of transmitted HIV-1 drug resistance","volume":"25","author":"Gifford","year":"2009","journal-title":"Bioinformatics"},{"key":"2020101604545994300_dkaa309-B41","doi-asserted-by":"crossref","first-page":"e0172206","DOI":"10.1371\/journal.pone.0172206","article-title":"Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome","volume":"12","author":"Abram","year":"2017","journal-title":"PLoS One"},{"key":"2020101604545994300_dkaa309-B42","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.3390\/v6093428","article-title":"Low-frequency NNRTI-resistant HIV-1 variants and relationship to mutational load in antiretroviral-na\u00efve subjects","volume":"6","author":"Gupta","year":"2014","journal-title":"Viruses"},{"key":"2020101604545994300_dkaa309-B43","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1093\/jac\/dky198","article-title":"Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing","volume":"73","author":"Nguyen","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2020101604545994300_dkaa309-B44","year":"2019"},{"key":"2020101604545994300_dkaa309-B45","doi-asserted-by":"crossref","first-page":"9040","DOI":"10.1073\/pnas.1820333116","article-title":"Mutations in the HIV-1 envelope glycoprotein can broadly rescue blocks at multiple steps in the virus replication cycle","volume":"116","author":"Van Duyne","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020101604545994300_dkaa309-B46","doi-asserted-by":"crossref","first-page":"e00922","DOI":"10.1128\/mBio.00922-17","article-title":"Mutations located outside the integrase gene can confer resistance to HIV-1 integrase strand transfer inhibitors","volume":"8","author":"Malet","year":"2017","journal-title":"mBio"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/11\/3311\/33893250\/dkaa309.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/11\/3311\/33893250\/dkaa309.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T23:49:39Z","timestamp":1667087379000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/11\/3311\/5878174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,29]]},"references-count":46,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,7,29]]},"published-print":{"date-parts":[[2020,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa309","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11]]},"published":{"date-parts":[[2020,7,29]]}}}